Cas:6946-46-9 ethyl 10-chloro-10-oxodecanoate manufacturer & supplier

We serve Chemical Name:ethyl 10-chloro-10-oxodecanoate CAS:6946-46-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

ethyl 10-chloro-10-oxodecanoate

Chemical Name:ethyl 10-chloro-10-oxodecanoate
CAS.NO:6946-46-9
Synonyms:9-ethoxycarbonylnonanoic acid chloride;ethyl 9-chlorocarbonylnonanoate;ethyl 9-chloroformylnonanoate;9-chlorocarbonyl-nonanoic acid ethyl ester;9-ethoxycarbonylnonanic acid chloride;9-Chlorcarbonyl-nonansaeure-aethylester
Molecular Formula:C12H21ClO3
Molecular Weight:248.74600
HS Code:2918300090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:303.5ºC at 760 mmHg
Density:1.042g/cm3
Index of Refraction:1.451
PSA:43.37000
Exact Mass:248.11800
LogP:3.43570

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 9-ethoxycarbonylnonanoic acid chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9-Chlorcarbonyl-nonansaeure-aethylester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-chlorocarbonyl-nonanoic acid ethyl ester Use and application,9-chlorocarbonyl-nonanoic acid ethyl ester technical grade,usp/ep/jp grade.


Related News: But they’ll be subject to up to 14 days of mandatory quarantine once they’re back in the US. ethyl 10-chloro-10-oxodecanoate manufacturer But they’ll be subject to up to 14 days of mandatory quarantine once they’re back in the US. ethyl 10-chloro-10-oxodecanoate supplier Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. ethyl 10-chloro-10-oxodecanoate vendor The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant��s collection. ethyl 10-chloro-10-oxodecanoate factory A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.